Immunotherapy in cholangiocarcinoma.
Journal
Current opinion in gastroenterology
ISSN: 1531-7056
Titre abrégé: Curr Opin Gastroenterol
Pays: United States
ID NLM: 8506887
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
Cholangiocarcinoma is an aggressive heterogeneous group of cancers of the biliary epithelium and most patients are detected with advanced metastatic disease with poor prognosis. The therapeutic options are limited, and the current standard care as systemic therapy is still cytotoxic chemotherapy. With the understanding of the complex immune microenvironment in the liver and these cancers arising in the milieu of chronic inflammation, recent advances in immune oncology have transformed the landscape of cancer management with breakthroughs in the treatment of several solid tumors. With the advances of genome sequencing, subgroups of cholangiocarcinoma with hyper mutated status and rich in cancer neoantigen production may be susceptible to immunotherapies like cancer vaccines and immune checkpoint inhibitors by eliciting a host immune response resulting in tumor rejection or overcoming the immunosuppressive local tumor microenvironment. In this review, we look at the most recent evidence behind immunotherapy and its application in the treatment of cholangiocarcinoma. Though its utility is still in early development it shows great promise in improving response rates that may translate to durable disease control and improve clinical outcomes in this aggressive disease.
Identifiants
pubmed: 33507028
doi: 10.1097/MOG.0000000000000715
pii: 00001574-202103000-00007
doi:
Substances chimiques
Cancer Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-111Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 2015; 27:439–449.
Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018; 19:222–232.
Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision medicine. J Autoimmun 2019; 100:17–26.
Loeuillard E, Conboy CB, Gores G, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep 2019; 1:297–311.
Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 2017; 17:306–321.
Mazzoni A, Bronte V, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689–695.
Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer 2013; 109:2665–2674.
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016; 16:7–19.
Tsukagoshi M, Wada S, Yokobori T, et al. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci 2016; 107:116–122.
Satpathy A, Wu X, Albring J, et al. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145–1154.
El-Serag G. Risk factors for cholangiocarcinoma. Hepatology 2011; 54:173–184.
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57:69–76.
Takagi S, et al. Dendritic cells. T-cell infiltration, and grp94 expression in cholangiocellular carcinoma. Hum Pathol 2004; 35:881–886.
Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013; 144:829–840.
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 47:1003–1010.
Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res 2016; 22:470–478.
Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19:804–814.
Kaida M, Morita-Hoshi Y, Soeda A, et al. Phase 1 Trial of Wilms Tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011; 34:92–99.
Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005; 25:3575–3579.
Loffler MW, Chandran PA, Laske K, et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol 2016; 65:849–855.
Aruga A, Takeshita N, Kotera Y, et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. Clin Cancer Res 2013; 19:2224–2231.
Aruga A, Takeshita N, Kotera Y, et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. Transl Med 2014; 12:61.
Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013; 62:919–929.
Löffler MW, Chandran PA, Laske K, et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient [published correction appears in J Hepatol. 2017 Jan;66(1):252-253]. J Hepatol 2016; 65:849–855.
Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and preexisting antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463–469.
Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: current status and emerging strategies. World J Gastrointest Oncol 2015; 7:338–346.
Episto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6:955–964.
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013; 17:1609–1617.
Rizvi S, Khan S, Hallemeier C, et al. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15:95–111.
Gani F, Nagarajan N, Kim Y. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol 2016; 23:2610–2617.
Le D, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409–413.
Bang YJ, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028 [abstract]. Eur J Cancer 2015; 51: (Suppl. 3): S112.
Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020; 147:2190–2198.
Kim R, Kim D, Alese O, et al. A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). J Clin Oncol 2019; 37: (15_suppl): 4097–14097.
Floudas CS, Xie C, Brar G. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). J Clin Oncol 2019; 37: (4_suppl): 336–336.
Finn RS, Qin S, Ikeda M, et al. Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382:1894–1905.
Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, Phase I Trial (JVDF). Oncologist 2018; 23:1407–2136.
Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol 2017; 10:4.
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641–645.